French biotech tart-up EG 427 has successfully closed a 27 million-euro ($28.4 million) Series B financing round co-led by ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...

A French biotech fo­cused on de­vel­op­ing ge­net­ic med­i­cines for neu­ro­log­i­cal con­di­tions has se­cured €27 mil­lion in a Se­ries B raise to sup­port its lead pro­gram … ...

One explanation for this is our inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder ... to tamsulosin treatment comprises men with ...

Three decades after this debate, clean intermittent catheterization remains the preferred method to treat chronic urine retention and neurogenic bladder. Recent regulatory changes have recommended ...

Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma. ABLE-22: Safety and efficacy evaluation of ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...